Market Newsdesk

Datavault AI to Participate at the LD Micro Invitational XV

– Reminder: Investor business update call scheduled for today – April 3, 2025 at 11:00 am ET –

BEAVERTON, Ore.–(BUSINESS WIRE)–
Datavault AI Inc. (NASDAQ: DVLT), leading the way in AI data experience, valuation, and monetization, today announced Datavault AI’s CEO Nathaniel Bradley and CFO Brett Moyer will participate at the LD Micro Invitational XV being held on April 9-10, 2025. In addition, as previously announced, Datavault AI will host a business update conference call today, April 3, 2025, at 11:00 AM ET, to discuss recent developments and initiatives.

LD Micro Invitational XV
Location:	The Westin Grand Central, New York City
Date:	April 9-10, 2025
Topic:	Presentation and one-on-one meetings
Presentation:	April 10 – 12:00 PM ET
Webcast:	LD Micro Webcast

Presentation materials will also be posted on the Investor Relations portion of the company’s website. Interested investors may register to attend the conference here – Attendee Information.

Business Update Call Today

The Company will host a business update call on Thursday, April 3, 2025 at 11:00 am ET. The conference call will be available through a live webcast found here: Webcast | Datavault AI Corporate Update Call

Those without internet access or who wish to dial in may call: 1-833-366-1124 (domestic), or 1-412-317-0702 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Datavault AI call.

A webcast replay of the call will be available approximately one hour after the end of the call and will be available for 90 days, at the above webcast link. A telephonic replay of the call will be available through April 10, 2025, and may be accessed by calling 1- 877-344-7529 (domestic) or 1- 412-317-0088 (international) or Canada (toll free) 855-669-9658 and using access code 1346188.

A presentation will be accessible on Thursday, April 3, 2025, under the “Investors” section of the website at Datavault AI Events.

About Datavault AI Inc.

Datavault AI™^{(Nasdaq: DVLT) is leading the way in AI driven data experiences, valuation and monetization of assets in the Web 3.0 environment. The company’s cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Science and Data Science Divisions. Datavault AI’s Acoustic Science Division features WiSA®, ADIO® and Sumerian® patented technologies and industry-first foundational spatial and multichannel wireless HD sound transmission technologies with IP covering audio timing, synchronization and multi-channel interference cancellation. The Data Science Division leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation and secure monetization. Datavault AI’s cloud-based platform provides comprehensive solutions serving multiple industries, including HPC software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange® (IDE) enables Digital Twins, licensing of name, image and likeness (NIL) by securely attaching physical real-world objects to immutable metadata objects, fostering responsible AI with integrity. Datavault AI’s technology suite is completely customizable and offers AI and Machine Learning (ML) automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring. The company is headquartered in Beaverton, OR. Learn more about Datavault AI at www.DVLT.ai.}

Forward Looking Statements Disclaimer

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other securities laws. Words such as “expect,” “will,” “anticipates,” “estimates” and variations of such words and similar future or conditional expressions are intended to identify forward-looking statements. Such forward-looking statements, including statements herein regarding our business opportunities and prospects, strategy, future revenue expectations, licensing initiatives, recent funding and M&A activities as well as our plans to integrate acquired businesses and technologies, are necessarily based upon estimates and assumptions that, while considered reasonable by us and our management, are inherently uncertain. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various risks and uncertainties including, but not limited to, the following: the risk that we are unable to satisfy all closing conditions in connection with the senior notes issuance described above, and the acquisition of certain assets from CSI; our ability to successfully integrate all IP that we have acquired; risks regarding our ability to utilize the assets we acquire to successfully grow our market share; risks regarding our ability to open up new revenue streams as a result of the various agreements we have entered into and assets we have acquired; our current liquidity position and the need to obtain additional financing to support ongoing operations; general market, economic and other conditions; our ability to continue as a going concern; our ability to maintain the listing of our common stock on Nasdaq; our ability to manage costs and execute on our operational and budget plans; our ability to achieve our financial goals; the degree to which our licensees implement the licensed technology into their products, if at all; the timeline to any such implementation; risks related to technology innovation and intellectual property, and other risks as more fully described in our filings with the U.S. Securities and Exchange Commission. The information in this press release is provided only as of the date of this press release, and we undertake no obligation to update any forward-looking statements contained in this communication based on new information, future events, or otherwise, except as required by law.

1.	Formerly known as WiSA Technologies, Inc.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250403096982/en/

Investor Contact:

David Barnard, Alliance Advisors Investor Relations, 415-433-3777

[email protected]

KEYWORDS: United States North America Oregon

INDUSTRY KEYWORDS: Technology Mobile/Wireless Other Technology Audio/Video Software Networks Data Management Artificial Intelligence Consumer Electronics

MEDIA:

Logo

Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease

• Top-Line Data from Dry Eye Chamber Trial and Field Trial Expected in Q2 2025
• Pending Positive Results and Discussions with the FDA, New Drug Application Resubmission Expected Mid-Year 2025

LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the resubmission of the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease. Although no manufacturing or safety issues with reproxalap were identified, the FDA stated in the letter that the NDA “failed to demonstrate efficacy in adequate and well controlled studies in treating ocular symptoms associated with dry eyes” and that “at least one additional adequate and well controlled study to demonstrate a positive effect on the treatment of ocular symptoms of dry eye” should be conducted. The letter identified concerns with the data from the trial submitted to the NDA that may have affected interpretation of the results, which the FDA stated may be related to methodological issues, including a difference in baseline scores across treatment arms.

Per draft FDA dry eye disease guidance, to be considered for regulatory approval in the United States, efficacy in dry eye disease may be demonstrated with two symptom trials and two sign trials. Among other clinical trials of reproxalap, Aldeyra previously conducted two trials for ocular redness (a dry eye disease sign) in a dry eye chamber, and two dry eye disease symptom field (environmental exposure) trials, which were submitted as part of an initial NDA in November 2022. In November 2023, the FDA issued a Complete Response Letter to the initial NDA stating that at least one additional symptom trial was required. Following discussions with the FDA, and as part of a comprehensive strategy designed to account for disease heterogeneity and potential differences in clinical sites and environment, Aldeyra initiated three clinical trials assessing dry eye disease symptoms: a dry eye chamber trial, a clinical trial in a different dry eye chamber, and a six-week field trial. In August 2024, Aldeyra announced the achievement of the primary endpoint in the first dry eye chamber clinical trial of reproxalap, and the NDA was resubmitted in October 2024. A Type A meeting is expected to be held within approximately 30 days to discuss the Complete Response Letter for the resubmitted NDA and the ongoing clinical trials of reproxalap in dry eye disease.

In the second quarter of 2025, Aldeyra expects to announce top-line results from the ongoing dry eye disease field trial and the ongoing chamber clinical trial. Subject to positive results and discussions with the FDA, Aldeyra intends to resubmit the NDA mid-year 2025. The review period for the potential NDA resubmission is expected to be six months.

As of December 31, 2024, Aldeyra reported cash, cash equivalents, and marketable securities of $101 million. With a majority of costs for the ongoing dry eye clinical trials having occurred in 2024, the full-year 2025 costs of the trials are expected to be approximately $6 million.

“Pending positive results from the ongoing clinical trials and discussions with the FDA, we look forward to a potential NDA resubmission mid-year 2025,” stated Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra Therapeutics. “Reproxalap remains the only late-stage topical ocular therapy suitable for chronic administration to have potentially demonstrated acute reduction in ocular redness, as well as reduction in ocular discomfort, highlighting rapid and broad activity for both the signs and symptoms of dry eye disease.”

Conference Call & Webcast Information

Aldeyra will host a conference call at 5:00 p.m. ET today, April 3, 2025, to provide a regulatory update on reproxalap. The dial-in numbers are (833) 470-1428 for domestic callers and (404) 975-4839 for international callers. The access code is 287309. A live audio webcast of the conference call also will be accessible from the “Investors & Media” section of Aldeyra’s website at ir.aldeyra.com. A live webcast of the conference call will be available on the Investor Relations page of the company’s website at https://ir.aldeyra.com. After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for 90 days.

About Reproxalap

Reproxalap is an investigational new drug candidate in development for the treatment of dry eye disease and allergic conjunctivitis, two of the largest markets in ophthalmology. Reproxalap is a first-in-class small-molecule modulator of RASP, which are elevated in ocular and systemic inflammatory diseases. The mechanism of action of reproxalap has been supported by the demonstration of statistically significant and clinically relevant activity in multiple physiologically distinct late-phase clinical indications. Reproxalap has been studied in more than 2,500 patients with no observed safety concerns; mild and transient instillation site irritation is the most commonly reported adverse event in clinical trials.

About Aldeyra

Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-629, ADX‑248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. For additional information, please visit www.aldeyra.com.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Aldeyra’s future expectations, plans, and prospects, including without limitation statements regarding: the goals, opportunity, and potential for reproxalap; the costs, outcome and expected timing and the results of the ongoing dry eye disease clinical trials; the outcome and expected timing of discussions with the FDA the potential and the timing of a potential NDA resubmission; the outcome and timing of the FDA’s acceptance, review, or approval of the potential NDA resubmission for reproxalap and the adequacy of the data included in the initial NDA and resubmitted NDA, and expected to be included in the potential resubmitted NDA; the likelihood and timing of the exercise of the Option; and Aldeyra’s expectations regarding the labeling for reproxalap, if approved. Aldeyra intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as, but not limited to, “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “anticipate,” “project,” “on track,” “scheduled,” “target,” “design,” “estimate,” “predict,” “contemplates,” “likely,” “potential,” “continue,” “ongoing,” “aim,” “plan,” or the negative of these terms, and similar expressions intended to identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions, and uncertainties. Aldeyra is at an early stage of development and may not ever have any products that generate significant revenue. All of Aldeyra’s development timelines may be subject to adjustment depending on recruitment rate, regulatory review, preclinical and clinical results, funding, and other factors that could delay the initiation, enrollment, or completion of clinical trials. Important factors that could cause actual results to differ materially from those reflected in Aldeyra’s forward-looking statements include, among others, the timing of enrollment, commencement and completion of Aldeyra’s clinical trials, the timing and success of preclinical studies and clinical trials conducted by Aldeyra and its development partners; delay in or failure to obtain regulatory approval of Aldeyra’s product candidates, including as a result of the FDA not accepting Aldeyra’s regulatory filings, issuing a complete response letter, or requiring additional clinical trials or data prior to review or approval of such filings or in connection with resubmissions of such filings; the ability to maintain regulatory approval of Aldeyra’s product candidates, and the labeling for any approved products; the risk that prior results, such as signals of safety, activity, or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving Aldeyra’s product candidates in clinical trials focused on the same or different indications; the scope, progress, expansion, and costs of developing and commercializing Aldeyra’s product candidates; uncertainty as to Aldeyra’s ability to commercialize (alone or with others) and obtain reimbursement for Aldeyra’s product candidates following regulatory approval, if any; the size and growth of the potential markets and pricing for Aldeyra’s product candidates and the ability to serve those markets; Aldeyra’s expectations regarding Aldeyra’s expenses and future revenue, the timing of future revenue, the sufficiency or use of Aldeyra’s cash resources and needs for additional financing; the rate and degree of market acceptance of any of Aldeyra’s product candidates; Aldeyra’s expectations regarding competition; Aldeyra’s anticipated growth strategies; Aldeyra’s ability to attract or retain key personnel; Aldeyra’s commercialization, marketing and manufacturing capabilities and strategy; Aldeyra’s ability to establish and maintain development partnerships; Aldeyra’s ability to successfully integrate acquisitions into its business; Aldeyra’s expectations regarding federal, state, and foreign regulatory requirements; political, economic, legal, social, and health risks, public health measures, and war or other military actions, that may affect Aldeyra’s business or the global economy; regulatory developments in the United States and foreign countries; Aldeyra’s ability to obtain and maintain intellectual property protection for its product candidates; the anticipated trends and challenges in Aldeyra’s business and the market in which it operates; and other factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Aldeyra’s Annual Report on Form 10-K for the year ended December 31, 2024, which is on file with the Securities and Exchange Commission (SEC) and available on the SEC’s website at https://www.sec.gov/. Additional factors may be described in those sections of Aldeyra’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, expected to be filed with the SEC in the second quarter of 2025, and Aldeyra’s other filings with the SEC.

In addition to the risks described above and in Aldeyra’s other filings with the SEC, other unknown or unpredictable factors also could affect Aldeyra’s results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Aldeyra undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250403220331/en/

Investor & Media Contact:

Laura Nichols

Tel: (781) 257-3060

[email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Science Biotechnology Research Pharmaceutical Optical Health FDA Clinical Trials

MEDIA:

Posted on April 3, 2025 8:15 am

Ontrak Secures Medicaid Provider Designation in Two New States, Enhancing Direct Service Delivery Capabilities

Ontrak Secures Medicaid Provider Designation in Two New States, Enhancing Direct Service Delivery Capabilities

MIAMI–(BUSINESS WIRE)–
Ontrak, Inc (NASDAQ: OTRK), a leading AI-powered and telehealth-enabled behavioral healthcare company today announced that a new affiliated practice association has secured official Medicaid designation in two new states. The first is a midwestern state, as talks continue with a large Midwestern Health Plan regarding the potential implementation of its WholeHealth+ solution in their region. The second is a southeastern state that will enable enhancing its solutions for one of its customers and future prospects.

Medicaid affiliation enables Ontrak to operate as a direct value-based provider in addition to its historical operations as a vendor. As a value-based care provider, Ontrak can align the quality outcomes and HEDIS measures with medical cost savings and financial incentives that it shares with payor partners. In addition, classification as a value based provider gives payors greater flexibility to partner with Ontrak through a model that allows for fees to become part of the medical cost ratio rather than an administrative vendor fee. And for Medicaid plans, it will allow for Ontrak to bill codes that are reimbursable at the State level. This shift is further enabling additional pipeline opportunities and provides payors optionality and flexibility in working with Ontrak.

“Securing these new Medicaid designations was a key step in advancing conversations with one of our major prospects, and enables Ontrak to more efficiently address a critical gap in mental health at the core of our solutions; delivering integrated behavioral health services to vulnerable populations,” said Brandon LaVerne, CEO. “Collectively, these Medicaid approvals further enable us to create opportunities for value-based partnerships with managed care organizations, health systems, and community-based providers across multiple states for Medicaid beneficiaries.”

Operating in the provider model, Medicaid designations are crucial in behavioral health, where access has often been limited for underserved communities. Official recognition in various states allows us to tailor value-based care models to local needs while using insights from other regions. Ontrak will continue to operate as a vendor for existing customers and many new prospects who prefer this model, but will also continue seeking additional state Medicaid affiliations when appropriate to deliver enhanced services to customers or prospects.

About Ontrak Health

Ontrak Health (Nasdaq: OTRK) is a leading AI and technology-enabled behavioral healthcare company whose mission is to help improve the health and save the lives of as many people as possible. Ontrak identifies, engages, activates, and provides care pathways to treatment for the most vulnerable members of the behavioral health population who would otherwise fall through the cracks of the healthcare system. We engage individuals with anxiety, depression, substance use disorder, and chronic disease through personalized care coaching and customized care pathways that help them receive the treatment and advocacy they need, despite the socioeconomic, medical, and health system barriers that exacerbate the severity of their comorbid illnesses. The company’s integrated intervention platform uses AI, predictive analytics, and digital interfaces combined with dozens of care coach engagements to deliver improved member health, better healthcare system utilization, and durable outcomes and savings to healthcare payors.

Forward-Looking Statements

This press release contains “forward-looking” statements that are based on the Company’s beliefs and assumptions and on information currently available to the Company on the date of this press release and are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to, the expectations around a Midwestern Health Plan implementing Ontrak’s WholeHealth+ solution, the ability to leverage greater access to reimbursable fees within the medical cost ratio and our ability to close additional pipeline opportunities and convert them to customers. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control, which may cause actual results to differ materially from stated expectations. These risk factors include, among others, our ability to effectively improve the quality measures and boost performance scores for our customers and the impact of this solution on increasing the number of, and revenue from, our prospective customers. For a further list and description of the risks and uncertainties we face, please refer to our most recent Securities and Exchange Commission filings which are available on its website at http://www.sec.gov. Such forward-looking statements are current only as of the date they are made and based on information available to us on the date hereof, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250403870594/en/

Company Contact:

Brandon LaVerne

Chief Executive Officer

[email protected]

Investor Relations:

Ryan Halsted

Gilmartin Group

[email protected]

KEYWORDS: United States North America Florida

INDUSTRY KEYWORDS: Software General Health Professional Services Telemedicine/Virtual Medicine Data Management Technology Artificial Intelligence Health Insurance Public Relations/Investor Relations Insurance Audio/Video Communications Health

MEDIA:

Logo

CrowdStrike Appoints Alex Ionescu as Chief Technology Innovation Officer

World-renowned cybersecurity expert and founding platform architect rejoins CrowdStrike to advance the Falcon platform’s architectural advantage and lead OS vendor technical engagement

AUSTIN, Texas–(BUSINESS WIRE)–CrowdStrike (NASDAQ: CRWD), today announced that Alex Ionescu, the company’s founding chief architect and former vice president of endpoint engineering, has rejoined the company as chief technology innovation officer (CTIO). Ionescu will lead mission-critical initiatives to advance the architecture, resilience and innovation of the CrowdStrike Falcon® platform, with a strategic focus on deeper technical engagement with Windows, Mac and Linux operating systems.

As the founding chief architect of the Falcon platform, Ionescu played a foundational role in building the company’s industry-defining sensor and overall architectural direction. His return comes at a pivotal moment as CrowdStrike continues to define the future of cybersecurity for the AI era. In his new role, Ionescu will build a dedicated innovation team and deliver platform architectural advancements, positioning the Falcon platform to enter new market segments and address the next generation of nascent threats and adversaries. Ionescu will also lead CrowdStrike’s participation in the Microsoft Virus Initiative Program (MVI 3.0), working with Microsoft to advise on the implementation of the next-generation vendor security stack for Windows.

“Alex has proven himself to be one of the world’s foremost experts on low-level operating systems and kernel engineering. His return emphasizes CrowdStrike’s commitment to technical leadership, platform resilience and deepening our strategic technology partnerships with OS vendors,” said George Kurtz, founder and CEO, CrowdStrike. “With Alex driving our next chapter of platform innovation, we’re reinforcing the Falcon platform’s architectural leadership and providing the most powerful cybersecurity foundation in the industry.”

During his previous decade at CrowdStrike, Ionescu was instrumental in delivering the Falcon sensor’s lightweight, high-performance architecture. His technical leadership helped establish the platform advantages that continue to differentiate CrowdStrike today, and his return will fuel the company’s most forward-leaning engineering efforts. Most recently, Ionescu served in senior cybersecurity roles within the Canadian government, where he led national-level foreign signals intelligence initiatives as the technical director of platform operations and research. Having long worked with Microsoft on Windows kernel technologies, while also having spent time at Apple on the CoreOS platform team, and contributed to the Linux and open-source software community, he is widely respected as one of the world’s foremost experts in broad operating system internals and kernel-level security. Ionescu has also co-authored the last three editions of the seminal Windows Internals series and delivered technical seminars to companies and government agencies around the world for the last two decades.

“CrowdStrike’s mission has always been powered by innovative engineering, and I’m proud to return at a time when the stakes for the cybersecurity industry have never been higher,” said Alex Ionescu, chief technology innovation officer, CrowdStrike. “As adversaries evolve and the operating system landscape shifts, our ability to innovate at the deepest layers of the platform, where software meets hardware, will define the next era of AI-powered cybersecurity. I’m excited to help lead that evolution.”

About CrowdStrike

CrowdStrike (NASDAQ: CRWD), a global cybersecurity leader, has redefined modern security with the world’s most advanced cloud-native platform for protecting critical areas of enterprise risk – endpoints and cloud workloads, identity and data.

Powered by the CrowdStrike Security Cloud and world-class AI, the CrowdStrike Falcon® platform leverages real-time indicators of attack, threat intelligence, evolving adversary tradecraft and enriched telemetry from across the enterprise to deliver hyper-accurate detections, automated protection and remediation, elite threat hunting and prioritized observability of vulnerabilities.

Purpose-built in the cloud with a single lightweight-agent architecture, the Falcon platform delivers rapid and scalable deployment, superior protection and performance, reduced complexity and immediate time-to-value.

CrowdStrike: We stop breaches.

Learn more: https://www.crowdstrike.com/

Follow us: Blog | Twitter | LinkedIn | Facebook | Instagram

Start a free trial today: https://www.crowdstrike.com/free-trial-guide/

© 2025 CrowdStrike, Inc. All rights reserved. CrowdStrike and CrowdStrike Falcon are marks owned by CrowdStrike, Inc. and are registered in the United States and other countries. CrowdStrike owns other trademarks and service marks and may use the brands of third parties to identify their products and services.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250403340435/en/

Media Contact

Jake Schuster

CrowdStrike Corporate Communications

[email protected]

KEYWORDS: United States North America California Texas

INDUSTRY KEYWORDS: Software Networks Internet Artificial Intelligence Data Management Technology Carriers and Services Security

MEDIA:

Logo

Hidalgo County Criminal District Attorney’s Office Digitally Transforms Evidence Management with NICE Justice

DA’s Office for one of the most populous counties in Texas will deploy NICE’s AI-powered solution to ensure justice gets done

HOBOKEN, N.J.–(BUSINESS WIRE)–NICE (Nasdaq: NICE) today announced that the Hidalgo County Criminal District Attorney’s Office has selected NICE Justice, one of the AI-powered solutions in NICE’s Evidencentral platform, to digitally transform evidence management, move cases through the justice system faster, and ensure justice gets done. With approximately one million residents, Hidalgo County is one of the most populous counties in Texas.

The cloud-based NICE Justice solution will digitally transform how attorneys and office staff receive, interact with, manage and share digital evidence. Freed from dealing with discs, drives, emails, and logging into multiple systems to manage and prepare evidence, attorneys and staff can focus on building and presenting compelling cases. NICE Justice also features built-in AI and automation capabilities for object detection, automated case building, video and audio transcription and translation, optical character recognition (OCR), analytics and finding evidence connections. Additionally, NICE Justice enables customizable retention of case evidence in a cloud-based solution that is both scalable and secure.

Hidalgo County Criminal District Attorney Terry Palacios, said, “The Hidalgo County District Attorney’s Office is dedicated to seeking the truth and ensuring justice gets done, to giving victims a voice and prosecuting offenders vigorously and fairly. Digital evidence is essential to this mission, but without a system in place to manage our growing digital evidence intake, trial preparation, and comply with discovery obligations, staff can get overwhelmed. With our investment in NICE Justice, we’re leading the way in digitally transforming evidence management, to move cases through the justice system faster, and ensure defendants’ due process rights are protected through thorough and timely discovery.”

Chris Wooten, Executive Vice President, NICE, commented, “The manual work of managing digital evidence can slow the pace of justice. Powered by AI, analytics and workflow automation, NICE Justice removes the manual hurdles involved in managing digital evidence, so attorneys can focus on building cases, and get the complete view of the truth that justice demands.”

With a substantial criminal caseload of 24,000 to 30,000 cases annually, ranging from Class ’B’ Misdemeanors to Capital Felony offenses, the Hidalgo County District Attorney’s office receives evidence from more than 25 different law enforcement agencies. There is no uniform format or method for submitting evidence and most of it arrives on discs and thumb drives, without needed video players. The office also needs to comply with discovery mandates to share evidence with defense counsel which increases staff workload significantly. The cumbersome process of downloading, uploading and copying digital evidence is repeated thousands of times every week.

NICE Justice simplifies and streamlines evidence intake by providing a single, secure online portal for law enforcement agencies to share digital evidence. Uploaded evidence is automatically organized in NICE Justice digital case folders in the cloud to jumpstart case-building. With complete digital evidence consolidated in one place, and the ability to view video and other evidence chronologically on timelines, NICE Justice makes it easy to discover all the facts of a case, to ensure that victims’ rights are protected.

NICE Justice also features integrated tools to streamline trial preparation, such as the ability to create video clips, redact evidence, and transcribe and translate audio. The solution also provides a secure, seamless and fully trackable method for sharing discovery with defense attorneys, eliminating the need to manually copy evidence onto CDs and disks.

To learn more about NICE’s digital transformation solutions for Public Safety and Justice:

• Visit the NICE website by clicking here.
• Email [email protected] for more information.

About the Hidalgo County Criminal District Attorney’s Office

Under the leadership of District Attorney Toribio “Terry” Palacios​, the Hidalgo County Criminal District Attorney’s Office is dedicated to providing justice and protecting the people of Hidalgo County, directly impacting the lives of thousands of Hidalgo County families. With jurisdiction over all criminal cases, the Office takes a holistic approach to justice to reduce recidivism. The Office’s various divisions are laser-focused on ensuring justice. The Office participates in many events annually to promote awareness of key issues, including human trafficking and domestic violence. Located in the Rio Grande Valley on the US-Mexico border, Hidalgo County is one of the most populous counties in Texas. More info at https://www.hidalgocounty.us/ and https://hidalgocountyda.com/.

NICE Public Safety & Justice

With over 3,000 customers and 30 years of experience, NICE helps all types of public safety and criminal justice agencies, from emergency communications and law enforcement to prosecutors and courts, digitally transform how they manage digital evidence and data from beginning to end, to get to the truth faster. NICE’s Evidencentral platform features an ecosystem of integrated technologies that bring data together to give a single view of the truth, enabling public safety and justice agencies to do what they do better – whether it’s responding to incidents, investigating and building cases, or prosecuting crimes. With comprehensive digital transformation solutions that can be deployed across entire counties and states, NICE also helps everyone work better together, so justice flows more smoothly, from incident to court. https://www.nicepublicsafety.com

About NICE

With NICE (Nasdaq: NICE), it’s never been easier for organizations of all sizes around the globe to create extraordinary customer experiences while meeting key business metrics. Featuring the world’s #1 cloud native customer experience platform, CXone, NICE is a worldwide leader in AI-powered self-service and agent-assisted CX software for the contact center – and beyond. Over 25,000 organizations in more than 150 countries, including over 85 of the Fortune 100 companies, partner with NICE to transform – and elevate – every customer interaction. www.nice.com

Trademark Note: NICE and the NICE logo are trademarks or registered trademarks of NICE Ltd. All other marks are trademarks of their respective owners. For a full list of NICE’s marks, please see: www.nice.com/nice-trademarks.

Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements, including the statements by Mr. Wooten, are based on the current beliefs, expectations and assumptions of the management of NICE Ltd. (the “Company”). In some cases, such forward-looking statements can be identified by terms such as “believe,” “expect,” “seek,” “may,” “will,” “intend,” “should,” “project,” “anticipate,” “plan,” “estimate,” or similar words. Forward-looking statements are subject to a number of risks and uncertainties that could cause the actual results or performance of the Company to differ materially from those described herein, including but not limited to the impact of changes in economic and business conditions; competition; successful execution of the Company’s growth strategy; success and growth of the Company’s cloud Software-as-a-Service business; changes in technology and market requirements; decline in demand for the Company’s products; inability to timely develop and introduce new technologies, products and applications; difficulties in making additional acquisitions or difficulties or delays in absorbing and integrating acquired operations, products, technologies and personnel; loss of market share; an inability to maintain certain marketing and distribution arrangements; the Company’s dependency on third-party cloud computing platform providers, hosting facilities and service partners; cyber security attacks or other security breaches against the Company; privacy concerns; changes in currency exchange rates and interest rates, the effects of additional tax liabilities resulting from our global operations, the effect of unexpected events or geo-political conditions, such as the impact of conflicts in the Middle East that may disrupt our business and the global economy; the effect of newly enacted or modified laws, regulation or standards on the Company and our products and various other factors and uncertainties discussed in our filings with the U.S. Securities and Exchange Commission (the “SEC”). For a more detailed description of the risk factors and uncertainties affecting the company, refer to the Company’s reports filed from time to time with the SEC, including the Company’s Annual Report on Form 20-F. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company undertakes no obligation to update or revise them, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250403182580/en/

Corporate Media Contact

Christopher Irwin-Dudek, +1 201 561 4442, [email protected], ET

Investors

Marty Cohen, +1 551 256 5354, [email protected], ET

Omri Arens, +972 3 763 0127, [email protected], CET

KEYWORDS: United States North America New Jersey

INDUSTRY KEYWORDS: Legal Apps/Applications Technology Professional Services Software Networks Data Management Other Professional Services Artificial Intelligence

MEDIA:

Logo

Genius Sports’ FANHub Platform Powers Award-Winning Indy 500 Marketing Partnership with EchoPoint Media

• Partnership renewed after exceeding ticket sales goals
• New campaigns to use advanced segmentation strategies and dynamic creative

NEW YORK–(BUSINESS WIRE)–
Genius Sports Limited (“Genius Sports”) (NYSE:GENI) and EchoPoint Media today announced the renewal of their media partnership to promote the 2025 Indianapolis 500, one of the most iconic events in motorsports. The collaboration will build upon the innovative, data-powered marketing strategies that drove unprecedented sales for the race in 2024.

The renewed partnership comes after Genius Sports’ campaign for the 2024 Indy 500 was recognized in the Sports category at The Drum Awards, honoring the best work in the marketing and advertising industry. The campaign leveraged Genius Sports’ proprietary data and audience targeting capabilities to deliver ticket sales at a rate 45% more efficient than previous benchmarks.

“After the exceptional results and industry recognition our partnership garnered last year, renewing with Genius Sports was an easy decision,” said Hannah Lane, Senior Media Supervisor at EchoPoint Media. “Their unique ability to translate complex sports data into tangible marketing results gives us confidence that we’ll continue to connect with passionate racing fans and drive ticket sales for this year’s Indianapolis 500.”

The 2024 campaign stood out for its innovative use of Genius Sports’ motorsports data and real-time countdown clocks in ad creative, creating urgency that accelerated purchase decisions. The renewed partnership will expand on last year’s approach, incorporating first-party data, targeted audience insights, and contextual placements to reach motorsports enthusiasts across NASCAR, Formula 1, and other racing disciplines.

“We’re honored to continue our work with EchoPoint and such an important sporting event as the Indy 500,” said Josh Linforth, Chief Revenue Officer at Genius Sports.

“Our data-driven approach consistently delivers measurable results. For 2025, we’re enhancing our strategy with even more sophisticated audience segmentation and dynamic creative capabilities to build on last year’s success.”

The 109th Running of the Indianapolis 500 is scheduled for Sunday, May 25, 2025.

About Genius Sports

Genius Sports is the official data, technology and broadcast partner that powers the global ecosystem connecting sports, betting and media. Our technology is used in over 150 countries worldwide, creating highly immersive products that enrich fan experiences for the entire sports industry.

We are the trusted partner to over 400 sports organizations, including many of the world’s largest leagues and federations such as the NFL, EPL, FIBA, NCAA, NASCAR, AFA and Liga MX.

Genius Sports is uniquely positioned through cutting-edge technology, scale and global reach to support our partners. Our innovative use of big data, computer vision, machine learning, and augmented reality, connects the entire sports ecosystem from the rights holder all the way through to the fan.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250403392414/en/

Media Contacts:

Chris Dougan, Chief Communications Officer

+1 (202) 766-4430

[email protected]

KEYWORDS: United States North America Indiana New York

INDUSTRY KEYWORDS: Sports Entertainment Professional Services Events/Concerts Motor Sports Licensing (Sports) Data Management Technology Digital Marketing Data Analytics Marketing Advertising Communications

MEDIA:

Logo